☆ 4.7 Article

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

期刊

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

卷 63, 期 11, 页码 -

出版社

AMER SOC MICROBIOLOGY

DOI: 10.1128/AAC.01024-19

关键词

dalbavancin; lung epithelial lining fluid; pharmacokinetics; pharmacodynamics; pneumonia

类别

Microbiology Pharmacology & Pharmacy

资金

Durata Therapeutics
Allergan plc.

向作者/读者索取更多资源

Protocol

Reagent

摘要

Dalbavancin is a lipoglycopeptide antibiotic with a prolonged half-life. A phase 1 study assessed dalbavancin levels in epithelial lining fluid (ELF) in 35 healthy adults using ELF bronchial microsampling up to 168 h after administration of 1,500 mg dalbavancin. The penetration of dalbavancin into ELF was 36%. ELF levels of dalbavancin exceeded the MIC(90)s of Streptococcus pneumoniae and Staphylococcus aureus for >= 7 days.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Microbiology

Individual meropenem epithelial lining fluid and plasma PK/PD target attainment

Roxane Rohani, Paul R. Yarnold, Marc H. Scheetz, Michael N. Neely, Mengjia Kang, Helen K. Donnelly, Kay Dedicatoria, Sophie H. Nozick, Rachel L. Medernach, Alan R. Hauser, Egon A. Ozer, Estefani Diaz, Alexander V. Misharin, Richard G. Wunderink, Nathaniel J. Rhodes

Summary: This study aimed to investigate the difference in target attainment of meropenem between plasma and epithelial lining fluid (ELF). The study found that some patients did not achieve the target attainment in both plasma and ELF, and those who achieved target attainment in plasma did not necessarily have the same effect in ELF. Patients with a higher creatinine clearance rate may have poorer target attainment in ELF. Additionally, the dosage and loading dose may also affect the target attainment.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

添加到收藏夹

Article Infectious Diseases

Evaluation of intraosteoblastic activity of dalbavancin against Staphylococcus aureus in an ex vivo model of bone cell infection

Pierre Chauvelot, Celine Dupieux-Chabert, Lelia Abad, Aubin Souche, Tristan Ferry, Jerome Josse, Frederic Laurent, Florent Valour

Summary: The study demonstrated that dalbavancin has the ability to effectively eradicate intraosteoblastic reservoir of Staphylococcus aureus in bone and joint infections. It showed significant reduction in bacterial inoculum at both low concentration and standard therapeutic doses, with similar efficacy to vancomycin but less efficient than rifampicin. Dalbavancin was found to be the only molecule significantly active at a low concentration.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context

Amedeo De Nicolo, Giacomo Stroffolini, Miriam Antonucci, Jacopo Mula, Elisa Delia De Vivo, Jessica Cusato, Alice Palermiti, Giuseppe Cariti, Giovanni Di Perri, Silvia Corcione, Francesco Giuseppe De Rosa, Antonio D'Avolio

Summary: This study investigated the long-term plasma pharmacokinetics of dalbavancin in outpatients with ABSSSI or osteoarticular infections who were treated with either one or two doses of 1500 mg. The results showed that dalbavancin exposure exceeded previously suggested pharmacodynamic targets, indicating a need for optimization in the treatment of osteoarticular infections.

BIOMEDICINES (2021)

添加到收藏夹

Article Microbiology

Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions

N. Layios, C. Visee, V Mistretta, R. Denooz, N. Maes, J. Descy, F. Frippiat, S. Marchand, N. Gregoire

Summary: This article describes the population pharmacokinetics of temocillin administered via continuous infusion versus intermittent infusion in critically ill patients with pneumonia. The study also examines the penetration ratios of the drug in the epithelial lining fluid/plasma and determines the probability of achieving target concentrations for a range of MICs. The results show that continuous infusion provides better PK/PD indexes but still falls below recommended doses for systemic infections, unless the patient has moderate renal impairment.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Microbiology

Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects

Keith A. Rodvold, Justin Bader, Jon B. Bruss, Kamal Hamed

Summary: SPR206, a next-generation polymyxin, shows promise for treating multidrug-resistant (MDR) Gram-negative infections. A Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206's safety and pharmacokinetics in healthy volunteers. The study demonstrates the pulmonary penetration of SPR206 and supports its further development for the treatment of serious infections caused by MDR Gram-negative pathogens.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia

Zufei Zhang, Yogesh T. Patel, Jill Fiedler-Kelly, Hwa-Ping Feng, Christopher J. Bruno, Wei Gao

Summary: Ceftolozane/tazobactam (C/T) is a novel cephalosporin with tazobactam recently approved for hospital-acquired and ventilator-associated pneumonia. A study evaluated the pharmacokinetics of C/T in adult patients with nosocomial pneumonia, showing significant differences in distribution of ceftolozane and tazobactam in plasma and pulmonary epithelial lining fluid between pneumonia patients and healthy participants.

JOURNAL OF CLINICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Microbiology

Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses

Nicholas D. D. Walter, Jackie P. P. Ernest, Christian Dide-Agossou, Allison A. A. Bauman, Michelle E. E. Ramey, Karen Rossmassler, Lisa M. M. Massoudi, Samantha Pauly, Reem Al Mubarak, Martin I. I. Voskuil, Firat Kaya, Jansy P. P. Sarathy, Matthew D. D. Zimmerman, Veronique Dartois, Brendan K. K. Podell, Radojka M. M. Savic, Gregory T. T. Robertson

Summary: Tuberculosis lung lesions are complex and harbor heterogeneous microenvironments that influence antibiotic effectiveness. Major strides have been made recently in understanding drug pharmacokinetics in pulmonary lesions, but the bacterial phenotypes that arise under these conditions and their contribution to drug tolerance are poorly understood.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

添加到收藏夹

Article Immunology

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients

Timothy J. Carrothers, H. Maxime Lagraauw, Lars Lindbom, Todd A. Riccobene

Summary: A population pharmacokinetic model of dalbavancin was developed using data from 1124 pediatric patients. Simulations showed that single-dose regimens of dalbavancin had adequate pharmacokinetic/pharmacodynamic target attainment in pediatric patients.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa

Aaron J. Heffernan, Fekade B. Sime, Sazlyna Mohd Sazlly Lim, Saiyuri Naicker, Katherine T. Andrews, David Ellwood, Jeffrey Lipman, Keith Grimwood, Jason A. Roberts

Summary: The study found that simulating the components of the epithelial lining fluid antagonizes the bactericidal effect of amikacin on P. aeruginosa, even at high concentrations achieved.

DRUGS IN R&D (2021)

添加到收藏夹

Article Microbiology

In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model

Christian M. Gill, Kamilia Abdelraouf, David P. Nicolau

Summary: WCK 4282 demonstrated clinical exposure efficacies against various Enterobacterales and Pseudomonas aeruginosa isolates in animal experiments. It showed potential activity against cefepime-resistant strains, particularly those producing extended-spectrum beta-lactamase and cephalosporinase.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Microbiology

A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections

Sinenhlanhla Mtshali, Byron A. Jacobs

Summary: Physiologically based pharmacokinetic models have gained popularity in drug development and regulatory science. This study validates the model's effectiveness in predicting drug-drug interaction and the pharmacokinetics of antiretroviral and anti-TB drugs through mathematical solving and sensitivity analysis.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Epithelial lining fluid concentrations of ceftriaxone in children with community-acquired pneumonia

Yi-Ning Dong, Ya-Kun Wang, Qian Li, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Yi Zheng, Li-Yuan Tian, Dian-Ping You, Yue-E Wu, Wei Zhao

Summary: This study found that the concentration of ceftriaxone in epithelial lining fluid is 12 times higher than in plasma in children.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹

Article Microbiology

Pharmacokinetics/Pharmacodynamics of Caspofungin in Plasma and Peritoneal Fluid of Liver Transplant Recipients

Claire Pressiat, Nawel Ait-Ammar, Matthieu Daniel, Anne Hulin, Francoise Botterel, Eric Levesque

Summary: This study analyzed the pharmacokinetics/pharmacodynamics of caspofungin in plasma and peritoneal fluid samples from liver transplant recipients. The results showed that the concentration of caspofungin in peritoneal fluid was low, suggesting a potential risk of resistance.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Assessment of Epithelial Lining Fluid Partitioning of Systemically Administered Monoclonal Antibodies in Rats

E. Boger, T. Erngren, B. -M. Fihn, E. Leonard, K. Rubin, E. Backstrom

Summary: This study investigates the potential bias in the estimation of monoclonal antibody (mAb) concentrations in the epithelial lining fluid (ELF) using the bronchoalveolar lavage (BAL) method. It demonstrates that the unbalanced extraction of mAb and urea could lead to underestimated ELF concentrations, but the choice of lavage volume does not significantly affect the partitioning of mAb into ELF.

JOURNAL OF PHARMACEUTICAL SCIENCES (2023)

添加到收藏夹

Article Infectious Diseases

Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model

Jessica R. Tait, Hajira Bilal, Tae Hwan Kim, Abigail Oh, Anton Y. Peleg, John D. Boyce, Antonio Oliver, Phillip J. Bergen, Roger L. Nation, Cornelia B. Landersdorfer

Summary: The study showed that the combination of ceftazidime and tobramycin has a good bactericidal effect and can suppress resistance in hypermutable Pseudomonas aeruginosa strains. In vitro experiments simulating treatment regimens revealed that high-dose combination therapy is more effective against susceptible strains.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Microbiology

Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue

Michael W. Dunne, Sailaja Puttagunta, Craig R. Sprenger, Chris Rubino, Scott Van Wart, James Baldassarre

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

添加到收藏夹

Article Microbiology

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program

Sandra P. McCurdy, Ronald N. Jones, Rodrigo E. Mendes, Sailaja Puttagunta, Michael W. Dunne

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

添加到收藏夹

Article Immunology

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection

Michael W. Dunne, Sailaja Puttagunta, Philip Giordano, Dainis Krievins, Michael Zelasky, James Baldassarre

CLINICAL INFECTIOUS DISEASES (2016)

添加到收藏夹

Article Public, Environmental & Occupational Health

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies

Michael W. Dunne, George H. Talbot, Helen W. Boucher, Mark Wilcox, Sailaja Puttagunta

DRUG SAFETY (2016)

添加到收藏夹

Article Infectious Diseases

Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis

Yoav Barnea, Anat Lerner, Asaf Aizic, Shiri Navon-Venezia, Eleanor Rachi, Michael W. Dunne, Sailaja Puttagunta, Yehuda Carmeli

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)

添加到收藏夹

Article Economics

Assessing the economic value of avoiding hospital admissions by shifting the management of gram plus acute bacterial skin and skin-structure infections to an outpatient care setting

V. Ektare, A. Khachatryan, M. Xue, M. Dunne, K. Johnson, J. Stephens

JOURNAL OF MEDICAL ECONOMICS (2015)

添加到收藏夹

Article Immunology

Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age

Daniel Gonzalez, John S. Bradley, Jeffrey Blumer, Ram Yogev, Kevin M. Watt, Laura P. James, Debra L. Palazzi, Varsha Bhatt-Mehta, Janice E. Sullivan, Li Zhang, Jennifer Murphy, Xilla T. Ussery, Sailaja Puttagunta, Michael W. Dunne, Michael Cohen-Wolkowiez

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2017)

添加到收藏夹

Article Microbiology

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli

James A. Karlowsky, Heather J. Adam, Melanie R. Baxter, Andrew J. Denisuik, Philippe R. S. Lagace-Wiens, Andrew J. Walkty, Sailaja Puttagunta, Michael W. Dunne, George G. Zhanel

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

添加到收藏夹

Article Immunology

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety

Urania Rappo, Sailaja Puttagunta, Vadym Shevchenko, Alena Shevchenko, Alena Jandourek, Pedro L. Gonzalez, Amy Suen, Veronica Mas Casullo, David Melnick, Rosa Miceli, Milan Kovacevic, Gertjan De Bock, Michael W. Dunne

OPEN FORUM INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Infectious Diseases

Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections

Urania Rappo, Pedro L. Gonzalez, Sailaja Puttagunta, Karthik Akinapelli, Katelyn Keyloun, Patrick Gillard, Yan Liu, Michael W. Dunne

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)

添加到收藏夹

Article Immunology

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial

Michael W. Dunne, Steven Aronin, Anita F. Das, Karthik Akinapelli, Jeanne Breen, Michael T. Zelasky, Sailaja Puttagunta

Summary: This study compared the clinical and microbiological responses of different treatment regimens in patients with complicated urinary tract infections, and the results showed that sulopenem was not superior to the comparator regimen.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Immunology

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial

Michael W. Dunne, Steven Aronin, Anita F. Das, Karthik Akinapelli, Michael T. Zelasky, Sailaja Puttagunta, Helen W. Boucher

Summary: This study demonstrates that sulopenem is an effective alternative for the treatment of urinary tract infections, with superiority in infections caused by resistant pathogens.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Letter Immunology

Applying Desirability of Outcome Ranking End Points

Michael W. Dunne, Steven Aronin, Anita F. Das, Jayanti Gupta, Karthik Akinapelli, Michael T. Zelasky, Sailaja Puttagunta, Helen W. Boucher

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Letter Immunology

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections

Michael W. Dunne, Steven Aronin, Anita F. Das, Jayanti Gupta, Karthik Akinapelli, Jeanne Breen, Michael T. Zelasky, Sailaja Puttagunta

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.